Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Cadrenal Therapeutics, Inc. (CVKD) had Return on Tangible Equity of -138.92% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-2.50M |
|
-- |
|
-- |
|
$2.51M |
|
$-2.51M |
|
$0.02M |
|
$-2.50M |
|
$-2.50M |
|
$-2.50M |
|
$-2.50M |
|
$-2.50M |
|
$-2.50M |
|
$-2.51M |
|
$-2.51M |
|
2.41M |
|
2.41M |
|
$-1.04 |
|
$-1.04 |
|
| Balance Sheet Financials | |
$2.86M |
|
$0.00M |
|
$0.01M |
|
$2.86M |
|
$1.06M |
|
-- |
|
-- |
|
$1.06M |
|
$1.80M |
|
$1.80M |
|
$1.80M |
|
2.51M |
|
| Cash Flow Statement Financials | |
$-3.00M |
|
$0.00M |
|
$1.30M |
|
$4.01M |
|
$2.31M |
|
$-1.70M |
|
$0.25M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.68 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-138.92% |
|
|
Return on Tangible Equity |
-138.92% |
-87.23% |
|
-138.92% |
|
$0.72 |
|
$-1.25 |
|
$-1.25 |
|